Gilead Sciences stock falls 1.87 percent as guidance rises for 2026
Published on 10/04/2026 at 11:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock (ISIN US3755581036) closed at USD 144.74 on Nasdaq on October 2, 2026, down 1.87 percent from the prior close. The latest quarterly report combined 10.6 percent revenue growth with higher full-year sales guidance.
Guidance moves higher
According to Zacks on September 24, 2026, Gilead raised its 2026 product-sales guidance to USD 30.10 billion-USD 30.40 billion from USD 30.00 billion-USD 30.40 billion. Product sales excluding Veklury are projected at USD 29.80 billion-USD 30.10 billion, up from the previous USD 29.40 billion-USD 29.80 billion range.
The upgrade followed second-quarter 2026 revenue of USD 7.80 billion, compared with a consensus estimate of USD 7.37 billion, while revenue increased 10.6 percent year over year. Adjusted EPS was a loss of USD 6.75, narrower than the consensus loss of USD 7.07, according to Zacks.
HIV remains the growth engine
Gilead's Q2 product sales excluding Veklury rose 10 percent to USD 7.60 billion, while HIV product sales increased 12 percent to USD 5.69 billion. The comparison matters because the HIV portfolio supplied the clearest operating growth in the quarter, even as Veklury expectations moved lower.
MarketBeat lists a Moderate Buy consensus from 29 analysts, including 23 Buy ratings and six Hold ratings. Its average 12-month target is USD 158.78, with a high of USD 180.00 and a low of USD 123.00.
Analysts turn more selective
On October 1, 2026, MarketBeat reported that Zacks Research downgraded Gilead from Strong Buy to Hold. The move contrasts with the broader Moderate Buy consensus and gives the stock a more divided near-term signal after its earnings-driven guidance increase.
Stock value and trading snapshot
Gilead Sciences carried a market capitalization of USD 179.5 billion on October 2, 2026, while 4,786,425 shares traded on Nasdaq. The USD 144.74 close was USD 2.76 below the prior session's USD 147.50 close.
The operating figures provide the stronger counterweight to the daily decline: Q2 revenue beat consensus by USD 430 million, while adjusted EPS beat the loss estimate by USD 0.32. For investors, the central question is whether HIV growth and the raised 2026 outlook can offset the lower Veklury forecast.
Gilead Sciences stock closes at USD 144.74
Gilead Sciences stock closed at USD 144.74 on Nasdaq on October 2, 2026, with a daily change of minus 1.87 percent and market capitalization of USD 179.5 billion.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Trading venue: NASDAQ
- Price (as of October 2, 2026, 4:00 p.m. EDT): Closing price USD 144.74
- Market capitalization: USD 179.5 billion (as of October 2, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
